Three Chinese Biotechs Bag Late-Stage VC/PE Funding In February
Executive Summary
Evopoint, I-Mab Biopharma (Hangzhou) and MAXVAX extended their funding with series E and C rounds, respectively, in February, amid signs that biotech investor sentiment in China may be recovering.